Early results of combined Her-2/neu (HER2) immunotherapy using a HER2 peptide vaccine with concurrent trastuzumab for metastatic breast cancer.

被引：0
|
作者：
Webster, D.
Waisman, J.
MacLeod, B.
dela Rosa, C.
Higgins, D.
Fintak, P.
Childs, J.
Slota, M.
Salazar, L.
Disis, M.
机构：
[1] Oregon Hlth Sci Univ, Portland, OR 97201 USA
[2] Univ Washington, Seattle, WA 98195 USA
来源：
BREAST CANCER RESEARCH AND TREATMENT | 2006年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S79 / S80
页数：2
相关论文
共 50 条
  • [1] A phase I/II study of a HER2/neu (HER2) peptide vaccine plus concurrent trastuzumab.
    Webster, D. J.
    Waisman, J.
    Macleod, B.
    Dela Rosa, C.
    Higgins, D.
    Fintak, P.
    Childs, J.
    Slota, M.
    Salazar, L. G.
    Disis, M. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 107S - 107S
  • [2] Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
    Disis, Mary L.
    Wallace, Danelle R.
    Gooley, Theodore A.
    Dang, Yushe
    Slota, Meredith
    Lu, Hailing
    Coveler, Andrew L.
    Childs, Jennifer S.
    Higgins, Doreen M.
    Fintak, Patricia A.
    dela Rosa, Corazon
    Tietje, Kathleen
    Link, John
    Waisman, James
    Salazar, Lupe G.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (28) : 4685 - 4692
  • [3] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [4] HER2 overexpressing metastatic breast cancer.
    Spigel D.R.
    Burstein H.J.
    Current Treatment Options in Oncology, 2002, 3 (2) : 163 - 174
  • [5] Her2/Neu (HER2) Intratumoral Genetic Heterogeneity in Breast Cancer and Its Concurrent Axillary Metastases
    Astvatsaturyan, K.
    Bose, S.
    MODERN PATHOLOGY, 2013, 26 : 28A - 28A
  • [6] Her2/Neu (HER2) Intratumoral Genetic Heterogeneity in Breast Cancer and Its Concurrent Axillary Metastases
    Astvatsaturyan, K.
    Bose, S.
    LABORATORY INVESTIGATION, 2013, 93 : 28A - 28A
  • [7] LEVEL OF HER2/NEU GENE (HER2) AMPLIFICATION IN PRIMARY AND METASTATIC SITES IN HER2-POSITIVE METASTATIC BREAST CANCER AND RESPONSE TO TRASTUZUMAB(T)-BASED THERAPY
    Gullo, G.
    Bettio, D.
    Zuradelli, M.
    Giordano, L.
    Masci, G.
    Bareggi, C.
    Salvini, P.
    Venci, A.
    Santoro, A.
    ANNALS OF ONCOLOGY, 2010, 21 : 101 - 101
  • [8] Quantitative measurements of HER2 expression and HER2: HER2 dimerization identify subgroups of HER2 positive metastatic breast cancer patients with different probabilities of response to trastuzumab treatment
    Huang, W.
    Lipton, A.
    Leitzel, K.
    Ali, S. M.
    Fuchs, E. M.
    Weidler, J.
    Chappey, C.
    Sperinde, J.
    Tan, Y.
    Jin, X.
    Paquet, A.
    Winston, J.
    Petropoulos, C.
    Kostler, W. J.
    Bates, M.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S86 - S86
  • [9] Tolerability of neratinib in older adults with HER2 positive or HER2 mutated metastatic breast cancer.
    Lee, Jin Sun
    Yost, Susan Elaine
    Stiller, Tracey
    Blanchard, Suzette
    Padam, Simran
    Katheria, Vani
    Tang, Aileen
    Martinez, Norma
    Patel, Niki Himat
    Sedrak, Mina S.
    Waisman, James Ross
    Li, Daneng
    Sanani, Shamel
    Presant, Cary A.
    Mortimer, Joanne E.
    Yuan, Yuan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [10] The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.
    Kong, SY
    Kwon, Y
    Lee, DH
    Lee, JS
    Lee, ES
    Ro, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 48S - 48S
12345